ClinicalTrials.gg
CompletedNCT01343745Updated Oct 29, 2021

Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)

A Phase 2 interventional study of BDP/formoterol and BDP/formoterol in Mild Persistent Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.

Enrollment
75th of 85
18 · median 100
Started
2008
with 4 others
Phase 2
17 of 86
none open now
Registered
55th of 86
by date
Lead sponsor
9 of 86
Chiesi Farmaceutici S.p.A.

Among the 86 studies testing formoterol in Asthma, this one is the 75th largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2008, is one of 17 in phase 2, and was the 55th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing formoterol in Asthma, or all of them as a file.
02

Study summary

The aim of this exploratory investigation is to evaluate if the Forced Expiratory Volume in the 1st second (FEV1) measurements, fractional exhaled nitric oxide (FENO) and Provocative Concentration 20 (PC20) after Adenosine Monophosphate (AMP) bronchial challenge evaluated after administration of a fixed combination of a Long-acting Beta-2-agonist (LABA) and an Inhaled Corticosteroid (ICS) at increasing doses may be suitable to demonstrate a dose response.

03

Conditions studied

  • Mild Persistent Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients 18-50 years of age, who have signed an form.
  2. Clinical evidence of asthma
  3. naïve asthmatic patients
  4. at Screening Visit is >70 % of the predicted value and at least 2.0 L.
  5. between 18 and 35.
  6. Sensitivity to AMP at Screening Visit.
  7. FENO levels >25 ppb at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  1. Having received an product within 2 months of Screening Visit.
  2. Inability to comply with study procedures or with study treatment intake.
  3. Any significant lung disease which is considered by the investigator to be .
  4. Patients who suffer from (COPD)
  5. Previous or current smokers who have a smoking history greater than 5 pack years.
  6. Patients with any uncontrolled disease that might, in the judgment of the investigator, place the patients at undue risk or potentially compromise the results or interpretation of the study.
  7. Patients with >450msec at the Screening Visit.
  8. Patients with serum potassium \<3.5 mEq/L or >6 mEq/L.
  9. Intolerance/ or any to treatment with beta2-agonists and/or inhaled .
  10. Patients who have a history of alcohol or substance abuse that in the opinion of the Investigator may be of clinical significance.
  11. Patients who have undergone major surgery in the previous 3 months.
  12. Patients who have had an exacerbation of asthma, requiring treatment with oral steroids during the last month prior to Screening Visit.
  13. Patients treated with slow-release corticosteroids 2 months prior to Screening Visit.
  14. Patients currently treated with anti-IgE Antibodies.
  15. Patients who have had a respiratory tract infection within 4-weeks prior to Screening Visit.
  16. Females not willing to use effective measures such as oral contraceptive or intra-uterine device (IUD).
  17. Females who are pregnant, lactating or planning to become pregnant
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo pMDI

    Drug: Placebo

  • Experimental
    Low dose

    BDP/formoterol pMDI low dose

    Drug: BDP/formoterol

  • Experimental
    High dose

    BDP/Formoterol pMDI high dose

    Drug: BDP/formoterol

Interventions

  • DrugBDP/formoterol

    Drug page: FormoterolStudies of FormoterolFormoterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)

    Also known as: Foster

  • DrugBDP/formoterol

    Drug page: FormoterolStudies of FormoterolFormoterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)

    Also known as: Foster

  • DrugPlacebo

    pressurised metered dose inhaler

06

What researchers measure

Primary outcomes

  1. PC20 after AMP challenge

    Provocative Concentration of AMP causing a 20% fall in FEV1.

    Time frame: 4 h post dose

  2. Fractional Exhaled Nitric Oxide (FeNO)

    Fractional exhaled nitric oxide (ppb). FeNO is a biomarker measured in a breath test and it is a validated method for measuring the airway inflammation in asthma.

    Time frame: 4 h post dose

  3. Lung function

    FEV1 area under the curve from 0 to 4 hour post dose (AUC0-4h)

    Time frame: from 0 to 4 h post dose

Secondary outcomes

  1. FENO

    Fractional exhaled nitric oxide

    Time frame: 2 h post dose

07

Study locations

1 site
  • Respiratory Clinical Trials - Heart Lung Centre - Queen Anne Street Medical Centre
    London, W1G 8HU, United Kingdom
08

References and documents

Publications

  • O'Connor BJ, Collarini S, Poli G, Brindicci C, Spinola M, Acerbi D, Barnes PJ, Leaker B. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial. BMC Pulm Med. 2011 Dec 21;11:60. doi: 10.1186/1471-2466-11-60. PubMed 22188731 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2011
First posted
Apr 28, 2011
Start
Feb 2008
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01343745
Responsible party
Sponsor
First posted
Apr 28, 2011
Start date
Feb 2008
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Oct 29, 2021

Study contacts

Brian J O'Connor, MD
principal investigator · Heart Lung Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion